Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.

pharmaceutical industry
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Pharma’s Ghost Labs Find New Life
Pharma’s Ghost Labs Find New Life
Katarina Zimmer | Nov 1, 2019
Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Immune Cell Bank Bets on Future CAR T Success
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
Chemist Behind the Combined Oral Contraceptive Dies at 102
Chemist Behind the Combined Oral Contraceptive Dies at 102
Catherine Offord | Jul 2, 2019
George Rosenkranz was part of a team in Mexico City that first synthesized norethindrone in 1951.

Miracle Elixirs
Miracle Elixirs
Bob Grant | Apr 1, 2019
A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.
Opinion: The “Money Culture” in Academic Biomedical Research
Opinion: The “Money Culture” in Academic Biomedical Research
David Rubenson | Mar 29, 2019
A drive for revenue is damaging basic science.